2021-001459-15

Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study

Name: Clinical Trial 2021-001459-15
Creator: Medical University of Graz
Keywords: Type 1 Diabetes Mellitus, clinical trial

Medical University of Graz·EU Clinical Trials RegisterOngoing

Study focus

Disease/Condition: Type 1 Diabetes Mellitus

Sponsor & location

Primary sponsor: Medical University of Graz

Timeline & enrollment

Phase: N/A
Start date: N/A
End date: N/A

Primary outcome

Difference in the change of anti-SARS-CoV-2 spike protein immune response measured by antigen-binding Ig assay from baseline to Visit 3 (2-3 weeks after the second vaccination) between people with diabetes (all 4 groups pooled) and healthy controls.

ICD-10 classifications

Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications

Data source

Registry: EU Clinical Trials Register
Trial ID: 2021-001459-15
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for 2021-001459-15 through Pure Global AI's free database. This phase not specified trial is sponsored by Medical University of Graz and is currently Ongoing. The study focuses on Type 1 Diabetes Mellitus.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.